# Semaglutide: Research Overview — Peptide Medicine NY > A literature summary of semaglutide, the GLP-1 receptor agonist approved for type 2 diabetes, weight management, cardiovascular risk reduction, and MASH. Covers mechanism, landmark trial results, and safety cautions. An FDA-approved GLP-1 receptor agonist backed by more large randomized trials, across more indications, than any other compound covered here. ## The short version Semaglutide is a **GLP-1 receptor agonist** — a synthetic peptide that mimics a gut hormone the body releases after eating. It is the lead compound on this desk because its trial record is the largest and broadest of the four: FDA-approved for type 2 diabetes, chronic weight management, reducing cardiovascular events in adults with established heart disease, and (since 2025) a form of fatty liver disease called MASH. It is available as a once-weekly injection and a once-daily oral tablet. In the STEP 1 trial, weekly semaglutide produced a mean 14.9% body-weight reduction at 68 weeks versus 2.4% for placebo [19]. In SELECT, across more than 17,600 people with heart disease, it cut major cardiovascular events by 20% [18]. In FLOW, it reduced serious kidney-disease events by 24% in people with type 2 diabetes and chronic kidney disease [17]. The honest context: in a head-to-head trial, tirzepatide — a newer dual-receptor compound — outperformed semaglutide on weight loss by about 6.5 percentage points [16]. ## What it is Semaglutide is a 31-amino-acid synthetic analogue of human GLP-1, about 94% identical to the natural hormone. Two changes give it its defining property — a long half-life. One substitution blocks the enzyme that normally breaks GLP-1 down within minutes; a fatty side chain attached elsewhere causes it to bind reversibly to albumin, the most common protein in blood, which shields it from being cleared and stretches its effective half-life to roughly a week. That is the entire structural basis for once-weekly dosing. The oral tablet version is co-formulated with an absorption enhancer that lets a small fraction of the dose cross the stomach lining before it is broken down — oral bioavailability is still under 1%, which is why the tablet has to be taken on an empty stomach with minimal water. ## How it works Semaglutide activates GLP-1 receptors throughout the body. In the pancreas, it boosts insulin release only when blood sugar is already elevated and suppresses glucagon — a glucose-dependent mechanism that limits the risk of dangerously low blood sugar when it is used alone. It also slows how fast the stomach empties, which extends fullness after a meal and is part of why nausea is a common early side effect. The weight effect is mostly a brain effect, not a metabolic one. Semaglutide reaches appetite circuits in the hypothalamus and brainstem, activating neurons that signal fullness and suppressing the ones that drive hunger — reducing both how much someone eats and the background mental preoccupation with food that people commonly call "food noise" [21]. Beyond appetite and glucose, GLP-1 receptors in the heart and kidneys appear to drive separate protective effects, confirmed in large outcome trials [17][18]. ## What the research shows *Head-to-head against tirzepatide.* In a 72-week trial of 751 adults with obesity, tirzepatide produced significantly greater weight loss than semaglutide — 20.2% versus 13.7% (P<0.001) — making semaglutide the benchmark a newer dual-receptor compound has since surpassed [16]. *Weight management (STEP 1).* In 1,961 adults with overweight or obesity, weekly semaglutide 2.4 mg produced a mean 14.9% body-weight reduction at 68 weeks, versus 2.4% for placebo [19]. *Cardiovascular outcomes (SELECT).* In 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes, semaglutide reduced the combined rate of cardiovascular death, heart attack, or stroke by 20% relative to placebo (HR 0.80) [18]. *Kidney outcomes (FLOW).* In 3,533 adults with type 2 diabetes and chronic kidney disease, semaglutide reduced serious kidney-disease events by 24% relative to placebo (HR 0.76) [17]. *Cardiovascular outcomes, type 2 diabetes (SUSTAIN-6).* In 3,297 adults with type 2 diabetes at elevated cardiovascular risk, semaglutide reduced major cardiovascular events (HR 0.74) — though diabetic retinopathy complications were significantly more frequent in the semaglutide group (HR 1.76), tied to how fast blood sugar was corrected [22]. *Mechanism, in rodents.* Semaglutide's brain-circuit route to weight loss — reduced food intake and altered food preference without lowering energy expenditure — was mapped directly in mice and rats [21]. *Safety synthesis.* A dedicated review concludes the risk-benefit balance is favorable overall, with GI intolerance the dominant issue and unconfirmed pancreatic and thyroid cancer signals owing to low incidence [20]. ## Reported effects, cautions & safety Patient-review sites and research communities describe a consistent pattern. These accounts are **anecdotal, not clinical evidence** — drawn from drug-review sites and forums, not controlled studies. *Reported benefits:* a quieting of food-related thoughts within the first week or two; sharply reduced cravings for sugar and fried food; steady weight loss over months, usually tied to simply eating less; and, in people with diabetes, improved blood-sugar readings. A widely discussed secondary effect is reduced interest in drinking alcohol. *Reported downsides:* nausea is the dominant complaint, worst in the first weeks and after dose increases; distinctive sulfur-smelling burps come up more often than official lists suggest; constipation and diarrhea, sometimes alternating; acid reflux; early fatigue on injection day; and, in a smaller group, hair shedding tied to the pace of weight loss rather than the drug itself. *What the clinical record actually flags:* GI intolerance during dose escalation is the leading cause of discontinuation, and it is the drug's mechanism at work, not a rare reaction [20]. A boxed warning for thyroid C-cell tumors comes from rodent data; no confirmed human signal exists, but a personal or family history of medullary thyroid cancer or MEN-2 is a contraindication [20]. Gallbladder disease risk is genuinely increased, mostly attributed to the pace of weight loss itself [20]. Rapid blood-sugar correction can worsen existing diabetic retinopathy [20][22]. Substantial weight regain is documented after stopping — this is framed as chronic therapy, not a cure. ## Where it fits in Research Peptide Fundamentals Semaglutide anchors this desk — the compound with the most approved indications, the largest trials, and the longest real-world track record of the four. [Retatrutide](/retatrutide) extends the same underlying incretin-receptor mechanism further and posts bigger Phase 2 numbers, but without semaglutide's years of Phase 3 confirmation and regulatory approval behind it. [PT-141](/pt-141) and [GHK-Cu](/ghk-cu) work through entirely different systems — brain desire circuits and skin matrix biology, respectively — but share the same core lesson this desk keeps repeating: evidence quality varies enormously even within "research peptides," and the label alone settles nothing. See the [full comparison](/compare). --- This is a literature review from an editorial desk, not a clinic, a pharmacy, or a substitute for talking to a licensed prescriber.